We previously showed that apatinib, together with gefitinib, displayed significant antitumor properties in patients with NSCLC because of EGFR-TKI resistance related to T790M, under both in vitro and in vivo conditions (Li et al., 2017). Here, EGFR is linked to non-small cell lung carcinoma.